title: Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review.
abstract: The progression of fibrosis due to hepatitis C virus (HCV) recurrence after liver transplantation (OLT) is faster than in the pretransplant setting, leading to histologically documented cirrhosis within 5 years in 25% to 30% of cases. Whether it is associated with biliary complications or previous alcohol abuse, recurrent HCV is the main cause of graft failure and death after OLT. The most important donor risk factor for HCV recurrence is advanced donor age. The disease's course is even more aggressive if it is associated with anti-HCV positivity or graft steatosis. The type of calcineurin inhibitor does not seem to influence HCV recurrence. Avoiding or slowly tapering steroids has been associated with less disease recurrence, while steroid pulses to treat acute rejection episodes have been associated with a worse progression of fibrosis. Antiviral therapy (AT) is not always recommended in OLT patients, but is of some benefit. Fibrosis has been shown to ameliorate in sustained virological responders to AT and to progress significantly more in nonresponders. Using long-term maintenance, AT has recently been shown to increase the probability of biochemical and histological responses, regardless of the timing of the HCV recurrence. In conclusion, the donor- recipient match should be assessed to limit HCV recurrences and their severity; AT is recommended to reduce or reverse the progression of fibrosis.
authors.affiliation: Gastroenterology, Multivisceral Transplant Unit, Department of Surgical and Gastroenterological Sciences, Padua University, Padua, Italy.
authors.forename: E
authors.initials: E
authors.lastname: De Martin
authors.forename: M
authors.initials: M
authors.lastname: Senzolo
authors.forename: M
authors.initials: M
authors.lastname: Gambato
authors.forename: G
authors.initials: G
authors.lastname: Germani
authors.forename: A
authors.initials: A
authors.lastname: Vitale
authors.forename: F R
authors.initials: FR
authors.lastname: Russo
authors.forename: P
authors.initials: P
authors.lastname: Burra
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D018450:Disease Progression; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications* / Q000821:virology*; D016031:Liver Transplantation / Q000379:methods*; D018579:Patient Selection; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons